DelveInsight’s, “Cyclo-Oxygenase 2 Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Cyclo-Oxygenase 2 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Cyclo-Oxygenase 2 Inhibitors: Overview
COX-2 inhibitors are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2, COX-2, an enzyme responsible for inflammation and pain. Targeting selectivity for COX-2 reduces the risk of peptic ulceration and is the main feature of celecoxib, rofecoxib, and other members of this drug class. COX-2 appears to be related to cancers and abnormal growths in the intestinal tract. COX inhibitors have been shown to reduce the occurrence of cancers and pre-cancerous growths. COX-2 inhibitors have been found to be effective in suppressing inflammatory neurodegenerative pathways in mental illness, with beneficial results in trials for major depressive disorder as well as schizophrenia. The inhibition of COX-2 is paramount for the anti-inflammatory and analgesic function of the selective COX-2 inhibitor celecoxib.
The companies and academics are working to assess challenges and seek opportunities that could influence Cyclo-Oxygenase 2 Inhibitors R&D. The therapies under development are focused on novel approaches for Cyclo-Oxygenase 2 Inhibitors.
This segment of the Cyclo-Oxygenase 2 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cyclo-Oxygenase 2 Inhibitors Emerging Drugs
Bardoxolone methyl: Reata Pharmaceuticals
Bardoxolone is an investigational, once-daily, orally administered activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA has granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease (“ADPKD”). The European Commission has granted Orphan Drug designation in Europe to bardoxolone for the treatment of Alport syndrome.
ALLOD-2: Allodynic Therapeutics
Allodynic Therapeutics is a clinical-stage biopharma company engaged in developing an oral novel investigational therapeutic product candidate, naltrexone-acetaminophen (ALLOD-2), for the acute treatment of migraine. Naltrexone-acetaminophen is a non-addictive medication that can also potentially be effective for the preventive treatment of migraine and neuropathic pain. Naltrexone-acetaminophen combines naltrexone’s under-recognized analgesic properties with acetaminophen’s under-recognized emotional pain calming properties, simultaneously targeting physical and emotional pain, hence, enhancing the treatment outcomes. In addition, naltrexone-acetaminophen portrays two innovative features, naltrexone’s novel inhibition of the Toll-Like receptor-4 (TLR4) leading to the reversal of neuropathic pain with acetaminophen’s ability to potentiate other analgesics beyond its own contribution (e.g., creating a potential analgesic synergism). Naltrexone-acetaminophen has U.S. patents extending to 2037.
Further product details are provided in the report……..
This segment of the report provides insights about the different Cyclo-Oxygenase 2 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 25+ key companies which are developing the Cyclo-Oxygenase 2 Inhibitors. The companies which have their Cyclo-Oxygenase 2 Inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, Reata Pharmaceuticals.
DelveInsight’s report covers around 25+ products under different phases of clinical development like
Cyclo-Oxygenase 2 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cyclo-Oxygenase 2 Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclo-Oxygenase 2 Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Cyclo-Oxygenase 2 Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Cyclo-Oxygenase 2 Inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Bardoxolone methyl: Reata Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
DRGT 46: Tavanta Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
OX338: Orexo
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
NTM 004: Neumentum
Drug profiles in the detailed report…..
Inactive Products
Cyclo-Oxygenase 2 Inhibitors Key Companies
Cyclo-Oxygenase 2 Inhibitors Key Products
Cyclo-Oxygenase 2 Inhibitors- Unmet Needs
Cyclo-Oxygenase 2 Inhibitors- Market Drivers and Barriers
Cyclo-Oxygenase 2 Inhibitors- Future Perspectives and Conclusion
Cyclo-Oxygenase 2 Inhibitors Analyst Views
Cyclo-Oxygenase 2 Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Cyclo-Oxygenase 2 Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Cyclo-Oxygenase 2 Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Reata Pharmaceuticals
• Allodynic Therapeutics
• Promius Pharma
• Merck & Co.
• AFT Pharmaceuticals
• Kadmon Corporation
• Arthritis Innovation Corporation
• Simcere
• Immix Biopharma
• Sirnaomics
• Layerbio
• Jiangsu HengRui Medicine
• Orexo
• Neumentum
• Orbis Biosciences
• ARKAY Therapeutics
• Virios Therapeutics
• Addpharma
• Tavanta Therapeutics
• Astellas Pharma
• Teikoku Seiyaku
• YooYoung Pharmaceuticals
• Tremeau Pharmaceuticals
• MedWell Laboratories
• RaQualia Pharma
